|(what is this?)|
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147. Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.
- findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco
- Macmillan, ML; Couriel, D; Weisdorf, DJ; Schwab, G; Havrilla, N; Fleming, TR; Huang, S; Roskos, L; et al. (Mar 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood. 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|